Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AHCY | P23526 | 5/20 | 0.39 |
| ▸ | ADORA2A | P29274 | 3/20 | 0.35 |
| ▸ | SLC28A1 | O00337 | 1/20 | 0.35 |
| ▸ | SLC28A2 | O43868 | 1/20 | 0.35 |
| ▸ | ADA | P00813 | 1/20 | 0.34 |
| ▸ | DOT1L | Q8TEK3 | 3/20 | 0.34 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.34 |
| ▸ | PI4K2A | Q9BTU6 | 1/20 | 0.33 |
| ▸ | ENPP1 | P22413 | 1/20 | 0.33 |
| ▸ | P2RY1 | P47900 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2309313 | 0.80 | AHCY (0.46) | AHCYADORA2ASLC28A1SLC28A2ADA | |
| SCHEMBL2313775 | 0.76 | AHCY (0.39) | AHCYADORA2AADADOT1LPI4K2A | |
| SCHEMBL2313783 | 0.72 | AHCY (0.39) | AHCYADORA2AADADOT1LPI4K2A | |
| SCHEMBL2313778 | 0.71 | AHCY (0.41) | AHCYADORA2AADADOT1LPI4K2A | |
| SCHEMBL7217681 | 0.70 | AHCY (0.40) | AHCYADORA2AADADOT1LPI4K2A | |
| SCHEMBL12429686 | 0.68 | AHCY (0.44) | AHCYADORA2ASLC28A1SLC28A2ADA | |
| SCHEMBL12386690 | 0.66 | ADA (0.49) | AHCYADORA2ASLC28A1SLC28A2ADA | |
| SCHEMBL12386689 | 0.66 | PI4KA (0.47) | AHCYADORA2AADAADORA3PI4K2A | |
| SCHEMBL21123115 | 0.65 | AHCY (0.56) | AHCYADORA2ASLC28A1SLC28A2DOT1L | |
| SCHEMBL17633015 | 0.65 | AHCY (0.54) | AHCYDOT1L |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8513214-B2 | C4′-substituted-2-deoxyadenosine analogs and methods of treating HIV | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE DEPT. OF HEALTH AND HUMAN SERVICES (US) | 2013-08-20 | — | — | US | disclosed |
| US-20110190226-A1 | C4'-SUBSTITUTED-2-DEOXYADENOSINE ANALOGS AND METHODS OF TREATING HIV | THE GOV. OF THE U.S.A. AS REPRESENTED BY THE SECRETARY OF THE DEPT. OF HEALTH AND HUMAN SERVICES | 2011-08-04 | — | — | US | disclosed |
| EP-2207554-A2 | C4'-SUBSTITUTED-2-DEOXYADENOSINE ANALOGS AND METHODS OF TREATING HIV | The U.S.A. As Represented By The Secretary, Department Of Health And Human Services (US) | 2010-07-21 | — | — | EP | disclosed |
| WO-2009064387-A2 | C4'-SUBSTITUTED-2-DEOXYADENOSINE ANALOGS AND METHODS OF TREATING HIV | GOV'T OF THE U.S.A, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH & HUMAN SERVICES (US) | 2009-05-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110190226-A1 | C4'-SUBSTITUTED-2-DEOXYADENOSINE ANALOGS AND METHODS OF TREATING HIV | ADORA3, ADA, ADAR | AHCY 260/4885ADORA2A 5/4885SLC28A1 155/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.